Immune-related encephalopathy at nivolumab effective treatment of lung adenocarcinoma. A case report
https://doi.org/10.18027/2224-5057-2018-8-1-71-76
Abstract
Now the number of patients receiving immunotherapy with checkpoint inhibitors, including nivolumab, is growing all over the world. At the same time, there is a growing of immune-related adverse events in clinical practice, including rare ones. There is a case report of immune-related encephalopathy (grade 3) at patient with metastatic non-small cell lung cancer after complete response at nivolumab treatment.
About the Authors
D. I. Yudin
N. N. Blokhin Russian Cancer Research Center
Russian Federation
MD, PhD Med, Senior Researcher
Russian Federation
MD, PhD Med, Senior Researcher
K. K. Laktionov
N. N. Blokhin Russian Cancer Research Center
Russian Federation
MD, DSc Med, Head of Department
Russian Federation
MD, DSc Med, Head of Department
A. K. Allahverdiev
N. N. Blokhin Russian Cancer Research Center
Russian Federation
MD, DSc Med, Leading Researcher
Russian Federation
MD, DSc Med, Leading Researcher
K. A. Sarantseva
N. N. Blokhin Russian Cancer Research Center
Russian Federation
MD
Russian Federation
MD
G. A. Tkachenko
N. N. Blokhin Russian Cancer Research Center
Russian Federation
MD, PhD, medical psychologist
Russian Federation
MD, PhD, medical psychologist
I. E. Musayev
Pirogov Russian National Research Medical University (RNRMU)
Russian Federation
student
Russian Federation
student
V. V. Breder
N. N. Blokhin Russian Cancer Research Center
Russian Federation
MD, PhD Med, Leading Researcher
Russian Federation
MD, PhD Med, Leading Researcher
E. V. Reutova
N. N. Blokhin Russian Cancer Research Center
Russian Federation
MD, PhD Med, Senior Researcher
Russian Federation
MD, PhD Med, Senior Researcher
M. S. Ardzinba
N. N. Blokhin Russian Cancer Research Center
Russian Federation
MD, PhD Med
Russian Federation
MD, PhD Med
References
1. Проценко С.А., Антимоник С.Ю., Берштейн Л.М., Новик А.В., Носов Д.А., Петенко Н.Н., Семенова А.И., Чубенко В.А., Юдин Д.И. Практические рекомендации по коррекции иммуно-опосредованных нежелательных явлений // Злокачественные опухоли. 2017. №3. Спецвыпуск 2. С. 592–620. [Protsenko S.A., Antimonik S.Yu., Bershteyn L.M., Novik A.V., Nosov D.A., Petenko N.N., Semenova A. I., Chubenko V.A., Yudin D. I. Prakticheskie rekomendatsii po korrektsii immuno-oposredovannykh nezhelatel’nykh yavleniy. Zlokachestvennye opukholi. 2017. No. 3. Special issue 2. P. 592–620 (In Russ.)].
2. Borghaei H., Paz-Ares L., Horn L. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015. Vol. 373 (17). P. 1627-1639.
3. Brahmer J., Reckamp K. L., Baas P. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015. Vol. 373 (2). P. 123-135.
4. Лактионов К.К., Саранцева К.А., Бредер В.В., Реутова Е.В., Юдин Д.И., Лактионова Л.В. Результаты применения ниволумаба у больных с немелкоклеточным раком легкого в клинической практике ФГБУ РОНЦ им. Н.Н. Блохина МЗ РФ // Вопросы онкологии. 2017. Т. 63. №5. C. 3–7. [Laktionov K.K., Sarantseva K.A., Breder V.V., Reutova E.V., Yudin D. I., Laktionova L.V. Rezul’taty primeneniya nivolumaba u bol’nykh s nemelkokletochnym rakom legkogo v klinicheskoy praktike FGBU RONTs im. N.N. Blokhina MZ RF. Voprosy onkologii. 2017. Vol. 63. No. 5. P. 3–7 (In Russ.)].
5. Kao J.C., Liao B., Markovic S.N., Klein C. J., Naddaf E., Staff N.P., Liewluck T., Hammack J. E., Sandroni P., Finnes H., Mauermann M. L. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies. JAMA Neurol. 2017. Vol. 74 (10). P. 1216-1222. doi: 10.1001/jamaneurol. 2017.1912.
6. Larkin J., Chmielowski B., Lao C.D., Hodi F.S., Sharfman W., Weber J., Suijkerbuijk K.P. M., Azevedo S., Li H., Reshef D., Avila A., Reardon D.A. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or NivolumabAlone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist. 2017. Vol. 22 (6). P. 709–718. Epub 2017 May 11. doi: 10.1634/theoncologist. 2016-0487.
7. Richard K., Weslow J., Porcella S. L., Nanjappa S. A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis. Cancer Control. 2017. Vol. 24 (5). 1073274817729069. doi: 10.1177/1073274817729069.
8. Spain L., Walls G., Julve M., O’Meara K., Schmid T., Kalaitzaki E., Turajlic S., Gore M., Rees J., Larkin J. Neurotoxicity from immunecheckpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017. Vol. 28 (2). P. 377-385. doi: 10.1093/annonc/mdw558.
9. Tanaka R., Maruyama H., Tomidokoro Y., Yanagiha K., Hirabayashi T., Ishii A., Okune M., Inoue S., Sekine I., Tamaoka A., Fujimoto M. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. Jpn J. Clin. Oncol. 2016. Vol. 46 (9). P. 875–878. Epub 2016 Jul 5. doi: 10.1093/jjco/hyw090.
10. Zimmer L., Goldinger S.M., Hofmann L., Loquai C., Ugurel S., Thomas I., Schmidgen M., Gutzmer R., Utikal J.S., G ppner D., Hassel J.C., Meier F., Tietze J.K., Forschner A., Weishaupt C., Leverkus M., Wahl R., Dietrich U., Garbe C., Kirchberger M.C., Eigentler T., Berking C., Gesierich A., Krackhardt A.M., Schadendorf D., Schuler G., Dummer R., Heinzerling L.M. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur. J. Cancer. 2016. Vol. 60. P. 210–225. Epub 2016 Apr 13. doi: 10.1016/j. ejca. 2016.02.024
11. Raskin J., Masror P., Cant A., Snoeckx A., Hiddinga B., Kohl S., Janssens A., Cras P., Van Meerbeeck J.P. Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. Lung Cancer. 2017. Vol. 109. P. 74–77. Epub 2017 May 10. doi: 10.1016/j. lungcan. 2017.05.002.
12. Kawamura R., Nagata E., Mukai M., Ohnuki Y., Matsuzaki T., Ohiwa K., Nakagawa T., Kohno M., Masuda R., Iwazaki M., Takizawa S. Acute Cerebellar Ataxia Induced by Nivolumab. Intern Med. 2017. Vol. 56 (24). P. 3357–3359. Epub 2017 Dec 15. doi: 10.2169/internalmedicine. 8895-17.
13. Schneider S., Potthast S., Komminoth P., Schwegler G., B hm S. PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis. Case Rep. Oncol. 2017. Vol. 10 (2). P. 473–478. eCollection 2017 May-Aug. doi: 10.1159/000477162.
Review
For citations:
Yudin D.I., Laktionov K.K., Allahverdiev A.K., Sarantseva K.A., Tkachenko G.A., Musayev I.E., Breder V.V., Reutova E.V., Ardzinba M.S. Immune-related encephalopathy at nivolumab effective treatment of lung adenocarcinoma. A case report. Malignant tumours. 2018;8(1):71-76. (In Russ.) https://doi.org/10.18027/2224-5057-2018-8-1-71-76
Views:
871
Email this article 